Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy

Cancer Research

Volumn 60, Issue 24, 2000, Pages 7126-7132

  Mustjoki, Satu ^a   Sidenius, Nicolai ^b   Sier, Cornelis F M ^b   Blasi, Francesco ^b   Elonen, Erkki ^c   Alitalo, Riitta ^d   Vaheri, Antti ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c Division of Hematology   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; IDARUBICIN; METHOTREXATE; MITOXANTRONE; PLASMINOGEN; TIOGUANINE; UROKINASE RECEPTOR; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD LEVEL; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CELL ADHESION; CELL LYSATE; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LEUKOCYTE; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROGNOSIS; TUMOR CELL; URINALYSIS;

ACUTE DISEASE; ADULT; AGED; BONE MARROW; CASE-CONTROL STUDIES; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOBLOTTING; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKOCYTES; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; PHENOTYPE; PRECIPITIN TESTS; RECEPTORS, CELL SURFACE; TIME FACTORS;

EID: 0034671311     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Directed plasminogen activation at the surface of normal and malignant cells
2. The urokinase receptor
3. uPA, uPAR, PAI-1: Key intersection of proteolytic, adhesive and chemotactic highways?
4. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling
5. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration
6. The urokinase receptor is required for human monocyte chemotaxis in vitro
7. Identification of the urokinase receptor as an adhesion receptor for vitronectin
8. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor
9. The intact urokinase receptor is required for efficient vitronectin binding: Receptor cleavage prevents ligand interaction
10. Removal of domain D2 or D3 of the human urokinase receptor does not affect ligand affinity
11. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin
12. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain
13. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator
14. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect
15. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity
16. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria
17. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients
18. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer
19. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer
20. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance
21. The level of urokinase type plasminogen activator receptor is increased in serum of ovarian cancer patients
22. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis
23. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: Increased concentrations in rheumatoid arthritis
24. Elevated levels of receptor for urokinase plasminogen activator in patients with non-small cell lung cancer
25. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer
26. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: Relationship to classification and response to therapy
27. Cellular glycosylphosphati-dylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression
28. Soluble urokinase receptor released from human carcinoma cells: A plasma parameter for xenograft tumour studies
29. Shedding and cleavage of the urokinase receptor (uPAR): Identification and characterisation of uPAR fragments in vitro and in vivo
30. The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer
31. The urokinase receptor: Protein structure and role in plasminogen activation and cancer invasion
32. Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells
33. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors
34. Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients
35. Regulation of integrin function by the urokinase receptor
36. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling